{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:06:35Z","timestamp":1789275995406,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:00:00Z","timestamp":1614470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Platelet rich plasma (PRP) is an upcoming interventional therapy for the treatment of melasma. Its efficacy is due to the multiple growth factors present in it which decrease melanogenesis by various signal transduction pathways. The present study evaluated the efficacy of PRP as a standalone agent in treatment of melasma. This is an open labeled prospective trial. Forty patients were given intralesional PRP at once monthly interval. Three such PRP sessions were carried out and the patients were followed up for 3 months. Assessment was done by calculating the modified melasma area severity index score (mMASI) for each patient. Patients were also asked to self\u2010evaluate their improvement based on a scale. There was an average 54.5% reduction in the mMASI score at the end of the study. There was no relapse in any patient. This reduction was irrespective of the skin type, gender, and type of melasma. Patients self\u2010evaluation showed that more than 90% of the patients were pleased or very pleased with the results. There were no significant side effects. PRP appears to be a potential new therapy with significant efficacy in improving pigmentation of melasma, standalone as monotherapy.<\/jats:p>","DOI":"10.1111\/dth.14881","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T11:04:22Z","timestamp":1613473462000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Autologous intralesional platelet rich plasma improves melasma"],"prefix":"10.1155","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3110-000X","authenticated-orcid":false,"given":"Ankita","family":"Tuknayat","sequence":"first","affiliation":[{"name":"Department of Dermatology Government Medical College and Hospital  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvinder Pal","family":"Thami","sequence":"additional","affiliation":[{"name":"Department of Dermatology Government Medical College and Hospital  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Department of Dermatology Government Medical College and Hospital  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen Kaur","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Government Medical College and Hospital  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.3.424"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1998.00585.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199500102-00006"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-61-1-28"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/039139888701000111"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000239606.92676.cf"},{"key":"e_1_2_8_8_1","first-page":"429","article-title":"Platelet\u2010rich plasma: a milieu of bioactive factors","volume":"28","author":"Boswell SG","year":"2012","journal-title":"Art Ther"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2003.12.003"},{"key":"e_1_2_8_10_1","first-page":"155","article-title":"Platelet rich plasma in dermatology","volume":"5","author":"Monteiro MR","year":"2013","journal-title":"Surg Cosmet Dermatol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2012.02394.x"},{"key":"e_1_2_8_12_1","article-title":"Autologous platelet\u2010rich plasma for treating chronic wounds","volume":"10","author":"Martinez\u2010Zapata MJ","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2011.02280.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2011.01999.x"},{"key":"e_1_2_8_15_1","unstructured":"International cellular medicine society guidelines for PRP. Section 10 2011.http:\/\/www.cellmedicinesociety.org\/attachments\/370_Section%2010%20-%20Platelet%20Rich%20Plasma%20(PRP)%20Guidelines.pdf. Accessed May 29 2020."},{"key":"e_1_2_8_16_1","first-page":"1","article-title":"Response to intradermal autologous platelet rich plasma injection in refractory dermal melasma: report of two cases","volume":"18","author":"Yew CH","year":"2015","journal-title":"JUMMEC"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690060057005"},{"key":"e_1_2_8_18_1","first-page":"87","article-title":"Treatment of periorbital hyperpigmentation using platelet\u2010rich plasma injections","volume":"3","author":"Al\u2010Shami SH","year":"2014","journal-title":"Am J Dermatol Venereol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2014.26.3.401"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1524821"},{"key":"e_1_2_8_21_1","first-page":"1","article-title":"Platelet\u2010rich plasma treatment for melasma: a pilot study","volume":"00","author":"Sirithanabadeekul P","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1781755"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.11.002"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2003.10.023"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12348"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.14881","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dth.14881","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.14881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:58:12Z","timestamp":1764169092000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.14881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,28]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/dth.14881"],"URL":"https:\/\/doi.org\/10.1111\/dth.14881","archive":["Portico"],"relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,28]]},"assertion":[{"value":"2020-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14881"}}